

# Dementia Care Aware: Exciting Updates and New Horizons





UCS



#### **Joint Accreditation Statement**



In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and University of California, San Francisco. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy (ACPE)

Accreditation Council for Pharmacy (ACPE) and the American Nurses Credentialing Center (ANCC), to provide

continuing education for the healthcare team.

#### **Physician Continuing Education**

PACE designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)<sup>TM</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

#### Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hours.

#### **PA Continuing Medical Education**



PACE has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

#### **Social Work Continuing Education**



As a Jointly Accredited Organization, Partners for Advancing Clinical Education is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program.

Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this course receive 1.0 [Type – Clinical] continuing education credits.

#### **Disclosure of Unlabeled Use**

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

#### **Disclaimer**

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

### Financial Disclosures

PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

Dr. Anna Chodos, MD, MPH, faculty for this activity, has no relevant financial relationships. Dr. Zia Agha, MD, faculty for this activity, has no relevant financial relationships.

Dementia Care Aware was established, funded and supported by the California Department of Health Care Services (DHCS) from 2022-2024. The contents of this webinar may not necessarily represent the official views or policies of the State of California.





Please use the chat and Q&A functions to enter your questions throughout.

A recording and materials will be available on **dementiacareaware.org** at the end of this webinar.



CE/CME information will be available at the end of the hour.





- 1. Introductions
- 2. What DCA has accomplished in the last 2 years.
- 3. New directions:
  - New partnership with West Health!
  - Our core mission: early detection of dementia
  - Next steps after a positive screen: a dementia care pathway
- 4. Partner with us



### Learning Objectives

At the end of this session, learners will be able to:

- 1. Give 2 examples of Dementia Care Aware's accomplishments.
- 2. List 2 reasons why early detection of dementia is valuable for people living with dementia.
- 3. Describe a short screening approach for dementia in primary care, the Cognitive Health Assessment.
- 4. Implement 3 next steps in clinical care after a positive dementia screen.



### Today's speakers



Anna Chodos, MD, MPH Executive Director Dementia Care Aware



Zia Agha, MD Chief Medical Officer West Health Institute





# West Health

**West Health** is a family of nonprofit and nonpartisan organizations dedicated to lowering healthcare costs to enable seniors to successfully age in place with access to high-quality, affordable health and support services that preserve and protect their dignity, quality of life and independence.

The West Health Institute's areas of focus include geriatric emergency care, telehealth, aging services, healthcare costs, behavioral health, and dementia.

West develops or validates new models of care and creates tools and resources for health professionals, policymakers, and other stakeholders.








#### .....with barriers / pain points at each step of the journey

Barriers deep dive in appendix Potential opportunity area for West ( **X** ) Screening & Diagnosis **Monitoring & follow-up** 2 Treatment Low screening and referral rates<sup>1</sup> driven by provider DMTs: limited treatment efficacy and risk of side Patient cost burden of long-term care: Medicare attitudes and training (e.g., perceived lack of benefit, effects (e.g., ARIA) reimbursement for LTC is limited and there is often a concerns of increased complexity, limited experience high out-of-pocket cost burden for patients Symptomatics<sup>3</sup>: medication adherence challenges, with diagnostics) side effects, and stigma leading to concerns of Caregiver loss of productivity and health burden inappropriate use and poor outcomes Patient stigma causing resistance to seeking (mental & physical) for (informal) caregivers as well as assessment for symptoms (e.g., due to societal logistical burden of supporting treatment administration Provider reluctance to treat through DMTs due to perceptions and uncertainty) limited experience managing increased case Limited provision of specialized dementia care, as complexity Diagnostic complexity with multiple steps (e.g., only 20% of nursing homes surveyed by the National confirmatory dx) often requiring patient to visit multiple Institute on Ageing (NIA) had dementia care units<sup>2</sup> Patient reluctance to use DMTs given risk-benefit providers profile Access challenges (e.g., long wait times for cognitive Low levels of care coordination among providers and with payors, assessments, geographic and cost barriers to Amyloid leading to gaps in care, duplicated efforts, and poor outcomes PET scans) Overall complexity of navigating the end-to-end journey, from before symptoms appear to long-term management

1. Fewer than 33% of Medicare beneficiaries reported having a cognitive assessment in wellness checkups: Cognitive Assessment At Medicare's Annual Wellness Visit In Fee-For-Service And Medicare Advantage Plans; Jacobson 2019; Health Affairs | 2. NIA / NIH | 3. Marketed assets which are now used to impact cognitive consequences of Alzheimer's Disease as well as assets used to treat neuropsychiatric symptoms (e.g., depression, anxiety, agitation, aggression (e.g., atypical antispychotics such as brexpiprazole for agitation)

# Today's typical patient journey is highly complex and involves a wide range of stakeholders



1. Marketed assets which are now used to impact cognitive consequences of Alzheimer's Disease as well as assets used to treat neuropsychiatric symptoms (e.g., depression, anxiety, agitation, aggression (e.g., atypical antispychotics such as brexpiprazole for agitation)

2. Primary care providers (non-dementia trained)

3. 43% of PCPs say that they do not use standardized tools to assess familiarity / training in assessing dementia. Dementia-trained specialists have been shown to conduct a different mix of tests to assess symptoms of cognitive impairment than PCPs



Pillar

#### West Health: A Partner in Dementia Care

 What
 How

 Image: Comparison of the image of the imag

Focus on seniors with mild cognitive impairment (MCI) and ADOD, with potential spillover benefits to other brain health areas

Who

Q

Rationale Opportunity to drive meaningful impact by focusing on disease area with major societal burden

- ADOD impacts more seniors than any other neurodegenerative condition (~5-7M today, ~13M projected by 2050)<sup>1</sup>
- ADOD imposes unique challenges on caregivers, leading to significant societal costs (est. 18.4 billion hours of unpaid caregiving in 2023, valued at \$350B)<sup>1</sup>

Significantly improve care delivery for ADOD patients and caregivers, versus public health or R&D / innovation

Potential for **outsized impact on patients**, **caregivers**, **and system costs**, given known gaps relative to public health and R&D

 Limited scalable care delivery models today, with distinct efforts across individual providers (e.g., self-contained models like Kaiser)

 Concerted national policy agenda led by advocacy organizations like AIM, with many high-impact policies in play (e.g., National Plan to Address Alzheimer's Disease, CMS GUIDE model) Support integrated early intervention efforts in primary care to simplify patient journey and improve outcomes as treatments continue to evolve

Ability for WH to have **outsized impact** by filling **critical gap in care delivery** 

- Majority of ADOD patients remain undiagnosed (~59% of those with probable dementia)<sup>2</sup>, with numerous pain points along typical patient journey
- Momentum in the early intervention space across policy & advocacy organizations (e.g., BOLD Act)<sup>3</sup>, with exciting innovations coming to market (e.g., blood biomarker tests)

1. <u>ALZ Association</u>

2. <u>HopkinsMedicine</u>

<sup>3.</sup> Building Our Largest Dementia (BOLD) Infrastructure for Alzheimer's Act directs CDC to create public health infrastructure to support and promote dementia risk reduction, early detection and diagnosis, prevention of avoidable hospitalizations, and dementia caregiving

# West Health: A Partner in Dementia Care

#### Dementia Care Aware 2.0:

- Accelerate opportunities to improve patient outcomes by transforming dementia care through public & provider awareness, screening & diagnosis, and care pathways.
- Empower primary care teams to implement the most promising brain health and dementia care practices.
- Identify, expand, and scale DCA 2.0 reach and impact via novel partnerships e.g. AHA, GUIDE.
- Change the narrative around dementia treatment with a focus on brain health.






# Starting with early detection



## Why screen? Alzheimer's Dementia is Highly Prevalent

- **10.9%** of the US population over 65 has dementia due to Alzheimer's Disease (only one cause of dementia!). And 73% of those are age 75+.
- 720K live in California




Source: Rajan KB, et al. doi: 10.1002/alz.12362.

Source: Alzheimer's Association. 2024 Alzheimer's Disease Facts and Figures.



### Why Screen? to Address Disparities



Compared to older adults who identify as white:

- Those who identify as Black have roughly **2X** the risk of dementia
- Those who identify as
   Latino/Hispanic have **1.5X** the risk
- Among Asian populations, different groups appear to have a different level of risk.
- In California, Asians experienced the sharpest rise in dementia prevalence (746%) of any group from 2000-2018.
- 1. Kornblith E, et al. doi:10.1001/jama.2022.3550
- 2. Mayeda, E.R., et al. doi.org/10.1016/j.jalz.2015.12.007
- 3. CA Alzheimer's Facts and Figures, 2021. Alzheimer's Association



This presentation and its contents are strictly confidential and proprietary to Dementia Care Aware and unauthorized use, disclosure, reproduction, or distribution, in whole or in part, without prior written permission from Dementia Care Aware is strictly prohibited.

### Our efforts to build the case for early detection



"A Brighter Future for Dementia Care, Early Detection Matters!" ~ video





# Accomplishments



## What DCA accomplished in 2 short years





2024

2023

HCS











#### Created the Cognitive Health Assessment









### Education and Training: Our Curriculum 2022-2024



#### **DEVELOPED AND COLLABORATED ON 8 COURSES**



#### WEBINAR ATTENDEES

**27 WEBINARS** averaging ~100 attendees each



**15 PODCAST EPISODES** 







### Reach: Trainees 2022-2024



INDIVIDUALS TRAINED ON CHA as of 10/2024



#### Percent of Clinical Providers Trained by County



#### MAJORITY CLINICAL LEARNERS

TRAINING PROVIDERS ACROSS CA – INCLUDING RURAL COUNTIES



## Training and support for providers and clinics



#### **Education and Training:**

- <u>Core</u>: CHA training
- More on-line training modules
- Bi-Monthly Webinars and Podcasts





# Warmline: 1-800-933-1789

 A provider support and consultation service staffed by Dementia Care Aware experts

#### Practice change support:

- UCLA Alzheimer's and Dementia Care program
- Alzheimer's Association
   Health Systems team
- Implementation guide


#### dementiacareaware.org DCA@ucsf.edu



### **Clinical implementation**



CHA's



#### CHAs Conducted By Insurance Type



3 PILOT LOCATIONS UCI, SFHN, LA DHS

#### PRIMARILY MEDI-CAL AND DUALS SCREENED

**IMPLEMENTATION GUIDE!** 






# New Directions



### Dementia Care Aware 2.0

Ensure all older adults and their caregivers receive the earliest possible dementia diagnosis and excellent care through capacity building and practice transformation in primary care.





## Continue and improve our training



#### Live trainings via webinar

• 2-3 times a month

For providers to bill, training is still required



修 On-line modules

• 8 courses available, will soon be updated



Live sessions as requested

• Please reach out if you want live training!



### **CALZHEIMER'S®** ASSOCIATION

Contact: Amanda Valenzuela avalenzuela@alz.org



## Promote the Cognitive Health Assessment

Screen patients older than age 65 annually (who don't have a pre-existing diagnosis of dementia)





### Tools for screening

	Administered to the patient:	Administered to the care partner:
Cognitive Screening Tools	<u>GP-COG</u> : Part 1: General Practitioner assessment of Cognition (for the patient) <u>Mini-Cog</u>	Short IQ-CODE: Short Informant Questionnaire on Cognitive Decline in the Elderly AD-8: Eight-Item Informant Interview to Differentiate Aging and Dementia
Functional Screening Tools	ADLs/IADLs: Activities of Daily Living and Instrumental Activities of Daily Living	<u>GP-COG</u> Part 2: General Practitioner Assessment of Cognition (for the informant) <u>FAQ</u> : Functional Activities Questionnaire



# The CHA: An opportunity to get started on brain health


• You can start a brain health plan at the very earliest signs of decline, in addition to treating medical or psychiatric causes of symptoms.

#### Brain Health Plan






### Next steps after a positive screen: our training



Course Handout: Next Steps After a Positive CHA		
University of California San Francisco		
Next Steps After a Positive Screen		
Introduction		
Dementia, a syndrome that's defined in the DSM V, is a new ("acquired")		



### Next steps after a positive screen: a care pathway





### Next steps after a positive screen: a care pathway



- Start brain health plan
- Plan follow-up visit

Principle 1: Don't wait to address brain health and symptoms. Start a brain health plan.

- Vision and hearing
- Reduce medications that affect cognition
- Encourage physical and social activity
- Address vascular risk factors: hypertension, diabetes, high LDL cholesterol

# Principle 2: Cognitive and functional decline can be assessed over multiple visits and needs active follow-up

Show patients and their caregivers how important this is and schedule follow-up to dive deeper into their symptoms



## Next steps after a positive screen: getting to a diagnosis

Start to get a deeper history

Next steps

evaluation

- Rule out causes and contributors
- Look for red flags

#### History:

#### Cognition

- > Ask questions about most or all cognitive domains.
- > Key information: trajectory of decline, severity of symptoms

#### Function:

- ➢ How did they perform ADLs and IADLs a few years ago? Now?
- > How might these changes be related to their cognitive decline?

#### Collateral:

When possible, get an observer or informant's report on the person's cognition and function.

#### Exam:

- > Physical exam looking for neurological findings, e.g. parkinsonism.
- > Cognitive testing when appropriate.
  - > Adapt your assessments and consider their background.



Next steps after a positive screen: getting to a diagnosis



Labs: B12, TSH, RPR, HIV

Imaging: Brain imaging

#### **Comorbid conditions:**

- ➤ Sleep apnea
- Substance use disorders
- Mental health conditions

DEMENTIA Care Aware

Next steps

evaluation

Start to get a

deeper history

Rule out causes

and contributors

Look for red flags

## Next steps after a positive screen: getting to a diagnosis




- Start to get a deeper history
- Rule out causes and contributors
- Look for red flags

# Red flags that suggest a referral to neurology or geriatrics is indicated.

- Rapid onset (<12 months)</p>
- Comorbidities that elevate risk: history of cancer, HIV
- Focal neurological findings
- Severe behavior changes
- ➢ Parkinsonism
- ➤ On anti-coagulation
- ➤ History of fall



### Next steps after a positive screen: communicating the diagnosis



#### Disclosure

- Disclosing is a key aspect of screening, diagnosis, and care planning.
- Patients and caregivers often report that they do not get a lot of time to discuss the diagnosis but rather get "diagnosed and adios".
- The more we can give time for conversation and planning next steps, the better.
- Revisit the conversation.



## Next steps after a positive screen: action plan



- Optimize function
- Caregiver support

#### An active care plan

- Involving caregivers
- Advance care planning and medical-legal planning
- Safety planning
- Focusing on function and cognition
- Constant reassessment and addressing symptoms



#### Next steps after a positive screen: connecting to resources Dementia Care Aware's resources page





#### bpc.cargiving.org

best programs for *guiding you to proven support for dementia care* 

Caregivers 

Professionals

A partnership between Benjamin Rose Institute on Aging and Family Caregiver Alliance

#### Find top-rated dementia caregiving programs near you.

Welcome! Best Programs for Caregiving is a free online directory of proven support programs for family and friend caregivers of individuals living with dementia. Whether you are a caregiver yourself or a professional whose organization serves dementia caregivers, you can use this tool to find and compare evidence-based programs from across the country that address caregivers' unique challenges and concerns. Choose a pathway below to access the database and get started.



Dementia Care Programs for Family Caregivers

BPC helps caregivers find and connect with the right support:



Dementia Care Program Info for Program Providers

BPC helps professionals support more caregivers:



### Next steps after a positive screen: implementation resources


#### Cognitive Health Assessment

#### **Implementation Guide**


A Practical Step-by-Step Guide to Cognitive Health Assessment (CHA) Implementation



Care Aware







# A world focused on early detection



## Factors moving us toward early detection

- Policy
  - D-SNPs required to report dementia screening rates
  - In California, generalists seeing 25% or more older adults in their practice have to do 20% of their continuing education in geriatrics or dementia (10 hours total). *You can get that for free at DCA!*
- Therapeutics
  - Diagnosis and treatment for Alzheimer's disease is changing quickly and it may be beneficial and possible to detect it much earlier.
- Programs
  - The GUIDE program for Medicare beneficiaries is a new dementia navigation program. Detection of dementia will open this benefit for many.



#### Partner with us!

This is not an easy road, but it's easier together.

CA is rich in resources to support people living with dementia.

We are looking for clinical partners that want to improve dementia care in their clinics through training and implementation support.









